And that's because, you know, to get to that level by the end of the fourth quarter, you're going to have to be at a run rate that would imply you're going to continue to do very well as you go into 27 and beyond. So with all that confidence that comes from doing the examination at a very refined level of script trends, position behavior, surveys that we do, behavior of patients on medicine, the market access picture. All of these things combine to give us a very good feeling about the direction we're traveling, and that's why we're able much earlier than expected to give this direction that we'll do at least a billion.

Feb 19, 2026 / receipt, needs a key / Will, CEO | earnings call 2026-02-19 | transcript de6a0297-c652-4b03-b130-a0459dc507b2 | chars 28287-28914 | segment 28

Increase Confidence to Raise Full-Year 2026 Guidance

ir_statement / Sep 15, 2026 / receipt

Filed sNDA with FDA in July in newly diagnosed MACLD patients

ir_statement / Sep 15, 2026 / receipt

Intend to submit data to PMDA in 2H:26 to support potential Japanese label expansion

ir_statement / Sep 15, 2026 / receipt